Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8241630 HER2 antibody composition

Patent 8241630 was granted and assigned to Genentech on August, 2012 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Martin Vanderlaan0

Yung-Hsiang Kao0

Date of Patent

August 14, 2012

0

Patent Application Number

129864700

Date Filed

January 7, 2011

0

Patent Citations Received

US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer

0

US Patent 11713358 Chimeric polypeptide assembly and methods of making and using the same

0

US Patent 11981744 Chimeric polypeptide assembly and methods of making and using the same

0

US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer

0

US Patent 12018084 Anti-CXCR2 antibodies and uses thereof

0

US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

0

US Patent 11654105 Subcutaneous HER2 antibody formulations

0

US Patent 11655305 Treatment of metastatic breast cancer

0

Patent Primary Examiner

Laura B Goddard

0

Patent abstract

A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8241630 HER2 antibody composition

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool